Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

David E. Gerber, Mark A. Socinski, Joel W. Neal, Heather A. Wakelee, Keisuke Shirai, Lecia V. Sequist, Rachel P. Rosovsky, Rogerio C. Lilenbaum, Bruno R. Bastos, Chao Huang, Melissa L. Johnson, Paul J. Hesketh, Deepa S. Subramaniam, Martin F. Dietrich, Feng Chai, Yunxia Wang, Julia Kazakin, Brian Schwartz, Joan H. Schiller, Julie R. BrahmerRonan J. Kelly

Hematology & Oncology
Internal Medicine

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Sort by
Weight
Alphabetically

Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer

Fingerprint

Medicine & Life Sciences